Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies-Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus.

IF 3.2 3区生物学 Q1 BIOLOGY

Life-Basel Pub Date : 2024-09-12 DOI:10.3390/life14091157

Brigitte Stephan, Anna Meineke, Matthias Augustin, Christina Sorbe

{"title":"Vaccination Rates in Patients with Chronic Inflammatory Skin Diseases and Immunomodulatory Systemic Therapies-Vaccinations against SARS-CoV-2, Influenza Virus or Varicella Zoster Virus.","authors":"Brigitte Stephan, Anna Meineke, Matthias Augustin, Christina Sorbe","doi":"10.3390/life14091157","DOIUrl":null,"url":null,"abstract":"Introduction: The national guidelines and the Standing Committee on Vaccination (STIKO) of the Robert Koch Institute (RKI) in Germany support preventive vaccinations for patients under immunomodulatory treatments.Material and methods: Retrospective analysis of data from patients with chronic inflammatory skin diseases from December 2021 to December 2022 with a focus on preventive vaccinations against influenza virus, varicella zoster virus, or SARS-CoV-2.Results: Patients with chronic inflammatory skin diseases were referred to our university outpatient's clinic for recommendations of systemic therapy. Vaccinations against influenza virus, varicella zoster virus, or SARS-CoV-2 were documented in 7365 analyzed patient files. A total of 79.7% were completely vaccinated against SARS-CoV-2, 49.7% patients were vaccinated against the influenza virus, and only 9.2% were completely vaccinated against varicella zoster virus.Discussion: In our patients who came for counselling before or during systemic treatment, vaccination rates against SARS-CoV-2, varicella zoster virus, or influenza virus were low. Patients age 60 and above had higher rates than the average German population of the same age, but still no satisfying protection.Conclusions: We suggest informing patients about preventive vaccination before and during systemic immunomodulatory treatments and emphasize the need for active communication in this vulnerable patient group.","PeriodicalId":56144,"journal":{"name":"Life-Basel","volume":null,"pages":null},"PeriodicalIF":3.2000,"publicationDate":"2024-09-12","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11433363/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Life-Basel","FirstCategoryId":"99","ListUrlMain":"https://doi.org/10.3390/life14091157","RegionNum":3,"RegionCategory":"生物学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q1","JCRName":"BIOLOGY","Score":null,"Total":0}

引用次数: 0

Abstract

Introduction: The national guidelines and the Standing Committee on Vaccination (STIKO) of the Robert Koch Institute (RKI) in Germany support preventive vaccinations for patients under immunomodulatory treatments.

Material and methods: Retrospective analysis of data from patients with chronic inflammatory skin diseases from December 2021 to December 2022 with a focus on preventive vaccinations against influenza virus, varicella zoster virus, or SARS-CoV-2.

Results: Patients with chronic inflammatory skin diseases were referred to our university outpatient's clinic for recommendations of systemic therapy. Vaccinations against influenza virus, varicella zoster virus, or SARS-CoV-2 were documented in 7365 analyzed patient files. A total of 79.7% were completely vaccinated against SARS-CoV-2, 49.7% patients were vaccinated against the influenza virus, and only 9.2% were completely vaccinated against varicella zoster virus.

Discussion: In our patients who came for counselling before or during systemic treatment, vaccination rates against SARS-CoV-2, varicella zoster virus, or influenza virus were low. Patients age 60 and above had higher rates than the average German population of the same age, but still no satisfying protection.

Conclusions: We suggest informing patients about preventive vaccination before and during systemic immunomodulatory treatments and emphasize the need for active communication in this vulnerable patient group.

查看原文本刊更多论文

慢性炎症性皮肤病和免疫调节系统疗法患者的疫苗接种率--SARS-CoV-2、流感病毒或水痘带状疱疹病毒疫苗。

导言：德国罗伯特-科赫研究所（RKI）的国家指导方针和疫苗接种常设委员会（STIKO）支持为接受免疫调节治疗的患者接种预防性疫苗：回顾性分析2021年12月至2022年12月慢性炎症性皮肤病患者的数据，重点关注流感病毒、水痘带状疱疹病毒或SARS-CoV-2的预防接种：慢性炎症性皮肤病患者被转诊至我校门诊部，接受系统治疗建议。在分析的 7365 份患者档案中，记录了流感病毒、水痘带状疱疹病毒或 SARS-CoV-2 疫苗接种情况。共有 79.7% 的患者完全接种了 SARS-CoV-2 疫苗，49.7% 的患者接种了流感病毒疫苗，只有 9.2% 的患者完全接种了水痘带状疱疹病毒疫苗：讨论：在接受系统治疗前或治疗期间前来咨询的患者中，SARS-CoV-2、水痘带状疱疹病毒或流感病毒的疫苗接种率较低。60 岁及以上患者的接种率高于德国同龄人的平均接种率，但仍无法提供令人满意的保护：我们建议在全身免疫调节治疗前和治疗期间告知患者有关预防性疫苗接种的信息，并强调在这一易受伤害的患者群体中进行积极沟通的必要性。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Life-Basel Biochemistry, Genetics and Molecular Biology-General Biochemistry,Genetics and Molecular Biology

CiteScore

4.30

自引率

6.20%

发文量

1798

审稿时长

11 weeks

期刊介绍： Life (ISSN 2075-1729) is an international, peer-reviewed open access journal of scientific studies related to fundamental themes in Life Sciences, especially those concerned with the origins of life and evolution of biosystems. Our aim is to encourage scientists to publish their experimental and theoretical results in as much detail as possible. There is no restriction on the length of the papers.